CDT Equity (CDT) Stock Price

CDT Equity Price

NYSE·CLOSED
0.05
​
Market closed

CDT Equity's net margin stands at -1.4%, broadly stable from -1.9% several years earlier.

CDT Equity stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CDT Equity business model & stock analysis

CDT Equity Inc generates revenue through the development and commercialization of clinical assets targeting unmet medical needs. The company focuses on disease-agnostic life science solutions, with key assets including AZD1656, a glucokinase activator for diabetes mellitus and Hashimoto’s Thyroiditis treatment, and AZD5904, a myeloperoxidase inhibitor for idiopathic male infertility. These assets are licensed for use in autoimmune diseases, immunodeficient conditions, and specific medical applications like uveitis, preterm labor, and renal transplant rejection. Pharmaceutical companies and healthcare providers purchase these clinical assets for research and therapeutic development. The company’s revenue streams derive from licensing agreements and commercial partnerships for its pipeline products. AZD1656 is positioned as a treatment option for Hashimoto’s Thyroiditis and Graves’ disease, while AZD5904 targets idiopathic male infertility. The firm’s focus on autoimmune and immunodeficient conditions aligns with healthcare providers seeking innovative therapies for complex patient populations. Licensing deals with pharmaceutical firms drive the primary revenue model. CDT Equity Inc’s business model centers on developing and licensing clinical assets across multiple therapeutic areas. Its pipeline includes AZD1656 for diabetes and thyroid conditions, and AZD5904 for infertility and autoimmune disorders. The company collaborates with healthcare providers and pharmaceutical partners to advance these assets toward commercialization, generating income through licensing fees and future product sales.

Frequently asked questions about CDT Equity

Converted at the current exchange rate, the CDT Equity share trades at 0.05 EUR (0.05 USD).

The revenue cannot currently be calculated for CDT Equity.

The profit cannot currently be calculated for CDT Equity.

The P/E ratio cannot be calculated for CDT Equity at the moment.

The P/S cannot be calculated for CDT Equity currently.

The Eulerpool Quality Score for CDT Equity is 3/10.

The ISIN of CDT Equity is US20678X4034. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of CDT Equity is CDT. The ticker symbol is used to trade CDT Equity shares on the stock exchange.

Fair ValueTerminal
0.04 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Feb 3, 2022
ISIN
US20678X4034
Cusip
20678X106
Market capitalization
5.10 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1.54 %
Last updated Nov 6, 2026, 3:43 AM

CDT Equity Peer Group

All fundamentals and in-depth analysis of CDT Equity

Our stock analysis for CDT Equity stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CDT Equity. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.